Clinical trials and PicnicHealth are two approaches when it comes to advancing medical knowledge and improving patient outcomes. While both clinical trials and PicnicHealth have their strengths and limitations, it's important to understand the differences between the two when considering options for improving healthcare.

Whether or not you had the opportunity to attend the three action-packed days of ISPOR this year, we’ve got you covered with a summary of 4 major themes that emerged.

Managing an IgA nephropathy (IgAN) diagnosis, whether it's yours or that of a loved one, can feel incredibly overwhelming, isolating, and just plain difficult. These five content creators living with IgAN are giving hope to the community by sharing their real experiences, tips, and resources to remind you you’re not alone.

With increasing applications of real-world data (RWD) upstream in the drug development lifecycle, it’s critical to recognize that there is no one-size-fits-all approach. So how can one incorporate different types of data from patients into clinical trials? Through conversation with a panel of experts from the biopharma industry and health technology companies, we will discuss scenarios when patient-mediated, tokenized and/or site-based approaches are warranted. Gaelan Ritter, Sneha Kishnani, and Andrew Larsen share their unique perspectives on the importance of a tailored yet flexible strategy and the potential value this can unlock for researchers and patients alike.Watch the recorded webinar or read the transcript below to explore design considerations for incorporating different types of real-world data into clinical trials.

Although there is a large and diversified group of Asian Americans and Pacific Islanders (AAPI) in the United States, clinical trials and medical research frequently underrepresent this group. This underrepresentation result in a lack of knowledge about how particular medications and therapies affect AAPI people, potentially resulting in less effective or even hazardous medical interventions.

PicnicHealth is excited to announce that we are expanding our long-term partnership with Roche and Genentech to better understand brain health and accelerate neurological disease research using real-world data.

Sarah You is an IgAN Change Champion who has used her challenges with IgA nephropathy to help others. Sarah was diagnosed with IgAN when she was 21 years old, living as an international student in the US. She flew back to receive treatment and be with her family in Korea following her diagnosis. Now that she understands how to manage her IgAN, she has a master's degree in immunology and is currently applying to medical schools so she can be a support system for other rare disease patients.

This year, the FDA shed light on important, cross-cutting considerations for patient-level, real-world data to serve as an external control arm. Our new blog post highlights what you need to know - and the data you need to have - to conduct an externally controlled trial.

IgA nephropathy (IgAN) is a type of kidney disease that affects the glomeruli, the tiny filtering units within the kidneys. To diagnose and monitor IgAN, patients typically undergo a range of tests, including blood labs for kidney diseases, urine tests for kidney disease, and imaging studies.

CureDuchenne and PicnicHealth Announce Real-World Evidence-Focused Partnership to Incorporate Participant Medical Records into CureDuchenne Link

In the US, nearly two million kidney biopsies are performed each year at a rate of 175 procedures per million population. Kidney biopsies can reveal important information about kidney function and inform nephrologists about the possible cause of symptoms that brought the patient in for a visit in the first place.

Managing a chronic condition can be challenging, but there are tools to help patients monitor their health and manage their symptoms. From wearable health monitors to online medical record platforms, blood pressure monitors, symptom-tracking apps, and diet-tracking tools, patients have a variety of resources at their disposal. Here are six tools that can help you take control of your health and manage your IgA Nephropathy:

There are many organizations dedicated to helping patients with IgA nephropathy. Here are five of the top organizations that IgA nephropathy patients can turn to for support and resources.

If you’ve been diagnosed with IgAN or suspect that you may have the disease, finding a knowledgeable and experienced nephrologist or IgAN specialist is crucial to managing your symptoms and receiving appropriate treatment. But where do you start?

The studies presented at the HTRS Scientific Symposium showcase some of the many ways PicnicHealth is partnering with leading researchers to deliver robust real-world evidence and improving patient care across different therapeutic areas, including rare diseases, hematology, immunology, neurology, and oncology

A kidney transplant is a surgical procedure where a healthy kidney is placed into a patient whose kidneys no longer function properly. The healthy kidney comes from either a living or deceased donor. End-stage renal disease occurs when a patient’s kidneys lose the ability to filter fluid and waste from the body, leaving harmful levels of waste behind.

IgA nephropathy (IgAN) is a kidney disease that can cause inflammation and damage to the kidneys due to the deposition of the immunoglobulin A (IgA) protein in the tiny filters in the kidneys, called ‘glomeruli’, which can lead to kidney dysfunction. The diagnostic process for IgAN usually involves a combination of tests to evaluate kidney function and determine the extent of damage.

PicnicHealth | Does a recent FDA approval signal changes for the wider industry when it comes to RWE?FDA approvals supported by Real-World Evidence (RWE) are rising. Life science companies would be remiss not to consider including evidence on the natural history of disease, unmet medical need, and/or patient-reported outcomes in their regulatory strategies. PicnicHealth has extensive experience helping life science companies execute strategies to leverage Real-World Data (RWD) and incorporate RWE into their research and business planning. Uncovering experiences and outcomes from real patients is at the heart of it all. Contact us to discuss how we can partner on confirmatory evidence studies to strengthen your regulatory submission.

The COVID-19 pandemic has had a significant impact on the lives of millions of people worldwide, including those with chronic conditions such as IgAN. Although there is limited research on the effects of COVID-19 on people with IgAN, it is crucial to take precautions and seek medical attention if you experience symptoms.

IgA Nephropathy (IgAN), also known as Berger’s disease, is a rare kidney disease that can cause issues with the kidneys’ ability to filter waste from the bloodstream. IgAN occurs when a compound called immunoglobulin A (IgA) builds up in excess within the kidneys, resulting in inflamed tissue and other complications. Thanks to modern treatment methods, IgAN can be effectively managed and its prognosis significantly improved. However, if left untreated, IgAN can lead to serious health problems, underscoring the importance of timely diagnosis and treatment.

IgA nephropathy, also known as IgAN or Berger’s disease is a type of kidney disease that occurs when there is an excess build-up of immunoglobulin-A (IgA) within the kidneys. If left untreated, this can cause inflammation of the kidneys and other complications that reduce the kidneys’ ability to efficiently filter waste products from the bloodstream.

IgAN, or IgA nephropathy, is a chronic kidney disease affecting millions worldwide. Despite its prevalence, many patients struggle to understand the symptoms of IgAN and how to manage the condition effectively. ‍This is a problem that the team at PicnicHealth is working hard to solve. Founded by Noga Leviner in 2014, PicnicHealth was created by a fellow patient to empower others to take complete ownership of their health records and manage their conditions confidently. In this guide, we will explore the symptoms of IgAN, also known as Berger’s Disease, and provide helpful tips for managing the condition.

This webinar explores relevant examples of how Data Science and Digital Health are accelerating pharmaceutical innovation and driving impact for patients. Bringing together global experts with diverse perspectives spanning regulatory, R&D and health tech, this conversation highlights innovative, RWD-driven approaches to drug development and regulatory decision-making. Najat, Noga, Jesper, and Evelyn discuss the need for different types of data to construct a complete clinical picture – and how a data-driven approach can drive impact across both research and clinical practice.

Sometimes, my experience with IBM leaves me feeling amazed at how hard it is to figure everything out.

It’s important us PA parents keep using our voices to push for more research.